Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
84.62%
Operating Margin
0.00%
Net Margin
117.47%
Efficiency Metrics
Revenue per Expense Ratio
-1,398,818,000.0
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
3,943,400,000.0%
EPS
-3.6100000000
Balance Sheet Analysis
Current Ratio
1.51
Cash Ratio
0.40
Working Capital
$1.81B
Debt to Equity
1.17
Debt to Assets
14.16%
Equity Ratio
12.07%
Cash Flow Analysis
Operating Cash Flow Ratio
-169.23%
Free Cash Flow Ratio
-140.86%
CapEx to Revenue
-28.37%
Dividends Paid
$1.52B
Stock Buybacks
$9.42B
Total Shareholder Returns
$10.94B
Cash Position Change
-10.44%
Key Takeaways (2023 FY)
Revenue declined by 171.57576197937%, indicating potential market challenges
Detailed Growth Metrics
Core Performance
Revenue
-171.58%
Net Income
-195.24%
EPS
-191.86%
Operating Income
-100.00%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
-0.11%
Operating Cash Flow
-55.94%
Free Cash Flow
-54.79%
Balance Sheet Health
Assets
13.90%
Debt
50.13%
Book Value per Share
-17.00%
Inventory
100.00%
Shareholder Returns
Dividends per Share
-16.90%
Shares Outstanding
20.22%
Long Term Trends
3Y Revenue/Share
-71.08%
5Y Revenue/Share
-410.79%
3Y Dividend/Share
-26.45%
5Y Dividend/Share
-39.77%